- Report
- January 2024
- 250 Pages
Global
From €7138EUR$7,950USD£6,079GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2918EUR$3,250USD£2,485GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2469EUR$2,750USD£2,103GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2469EUR$2,750USD£2,103GBP
- Report
- September 2024
- 82 Pages
Japan
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- October 2023
- 170 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- January 2022
- 111 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- January 2024
- 250 Pages
Global
€4485EUR$4,995USD£3,819GBP
- Drug Pipelines
- April 2021
- 78 Pages
Global
€19753EUR$22,000USD£16,821GBP
- Report
- October 2018
- 17 Pages
Global
From €8979EUR$10,000USD£7,646GBP
- Report
- October 2023
- 146 Pages
Global
From €3726EUR$4,150USD£3,173GBP
- Report
- August 2024
- 85 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2024
- 85 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2024
- 94 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- May 2022
- 54 Pages
Global
From €2245EUR$2,500USD£1,912GBP

Prostacyclin is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary arterial hypertension, deep vein thrombosis, and coronary artery disease. It works by inhibiting platelet aggregation and reducing the risk of blood clots. Prostacyclin is typically administered intravenously or subcutaneously, and is available in both generic and branded forms. It is also used in combination with other drugs to treat certain conditions.
The prostacyclin market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. These companies include Actelion Pharmaceuticals, Bayer AG, GlaxoSmithKline, Merck & Co., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more